6533b7ddfe1ef96bd1274588

RESEARCH PRODUCT

REMINET : A European, Multicenter, Phase II/III Randomized Double-Blind, Placebo-Controlled Study Evaluating Lanreotide As Maintenance Therapy after First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors

C. LepageL. DahanJ.-l. LegouxK. Le MalicotR. GuimbaudD. TougeronA. LievreN. BouariouaC. PetorinM. PavelI. BorbathC. ToumpanakisD. SmithM. DucreuxT. Walter

subject

Clinical trial[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismDuodeno-pancreatic neuroendocrine tumoursMaintenance[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismComputingMilieux_MISCELLANEOUS

description

International audience

https://u-bourgogne.hal.science/hal-01664217